Does the media favor TGTX or ZBIO?

In the previous week, TG Therapeutics had 7 more articles in the media than Zenas BioPharma. MarketBeat recorded 11 mentions for TG Therapeutics and 4 mentions for Zenas BioPharma. TG Therapeutics' average media sentiment score of 0.98 beat Zenas BioPharma's score of 0.14 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ZBIO or ORKA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Zenas BioPharma N/A -122.45% -58.04% Oruka Therapeutics N/A -21.65% -20.88%

Does the media refer more to ZBIO or ORKA?

In the previous week, Oruka Therapeutics had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 6 mentions for Oruka Therapeutics and 4 mentions for Zenas BioPharma. Oruka Therapeutics' average media sentiment score of 1.33 beat Zenas BioPharma's score of 0.14 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oruka Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ZBIO or CGON?

In the previous week, CG Oncology had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for CG Oncology and 4 mentions for Zenas BioPharma. CG Oncology's average media sentiment score of 0.77 beat Zenas BioPharma's score of 0.14 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is COGT or ZBIO more profitable?

Cogent Biosciences' return on equity of -84.47% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -84.47% -47.72% Zenas BioPharma N/A -122.45% -58.04%

Does the media prefer COGT or ZBIO?

In the previous week, Cogent Biosciences had 15 more articles in the media than Zenas BioPharma. MarketBeat recorded 19 mentions for Cogent Biosciences and 4 mentions for Zenas BioPharma. Cogent Biosciences' average media sentiment score of 0.87 beat Zenas BioPharma's score of 0.14 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MIRM or ZBIO?

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Zenas BioPharma. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 4 mentions for Zenas BioPharma. Mirum Pharmaceuticals' average media sentiment score of 1.29 beat Zenas BioPharma's score of 0.14 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Zenas BioPharma (ZBIO) Competitors

$33.77 +2.12 (+6.70%)

Closing price 04:00 PM Eastern

Extended Trading

$33.72 -0.05 (-0.15%)

As of 04:58 PM Eastern

Compare

ZBIO vs. TGTX, ORKA, CGON, COGT, and MIRM

Should you buy Zenas BioPharma stock or one of its competitors? Zenas BioPharma's main competitors and comparable companies include TG Therapeutics (TGTX), Oruka Therapeutics (ORKA), CG Oncology (CGON), Cogent Biosciences (COGT), and Mirum Pharmaceuticals (MIRM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zenas BioPharma compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Zenas BioPharma (NASDAQ:ZBIO) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

58.6% of TG Therapeutics shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

TG Therapeutics has a net margin of 55.22% compared to Zenas BioPharma's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Zenas BioPharma	N/A	-122.45%	-58.04%

TG Therapeutics presently has a consensus price target of $63.00, indicating a potential upside of 13.68%. Zenas BioPharma has a consensus price target of $45.71, indicating a potential upside of 35.37%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

TG Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.03, meaning that its stock price is 203% less volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.76	$447.18M	$2.74	20.23
Zenas BioPharma	$10M	220.11	-$377.74M	-$8.99	N/A

In the previous week, TG Therapeutics had 7 more articles in the media than Zenas BioPharma. MarketBeat recorded 11 mentions for TG Therapeutics and 4 mentions for Zenas BioPharma. TG Therapeutics' average media sentiment score of 0.98 beat Zenas BioPharma's score of 0.14 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

TG Therapeutics beats Zenas BioPharma on 11 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to Oruka Therapeutics?

Zenas BioPharma (NASDAQ:ZBIO) and Oruka Therapeutics (NASDAQ:ORKA) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Oruka Therapeutics' return on equity of -21.65% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-122.45%	-58.04%
Oruka Therapeutics	N/A	-21.65%	-20.88%

In the previous week, Oruka Therapeutics had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 6 mentions for Oruka Therapeutics and 4 mentions for Zenas BioPharma. Oruka Therapeutics' average media sentiment score of 1.33 beat Zenas BioPharma's score of 0.14 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oruka Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics has lower revenue, but higher earnings than Zenas BioPharma. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	220.11	-$377.74M	-$8.99	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Zenas BioPharma currently has a consensus price target of $45.71, suggesting a potential upside of 35.37%. Oruka Therapeutics has a consensus price target of $134.30, suggesting a potential upside of 31.90%. Given Zenas BioPharma's higher possible upside, research analysts plainly believe Zenas BioPharma is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

56.4% of Oruka Therapeutics shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zenas BioPharma has a beta of -1.03, meaning that its share price is 203% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the broader market.

Summary

Oruka Therapeutics beats Zenas BioPharma on 11 of the 14 factors compared between the two stocks.

How does Zenas BioPharma compare to CG Oncology?

Zenas BioPharma (NASDAQ:ZBIO) and CG Oncology (NASDAQ:CGON) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

26.6% of CG Oncology shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CG Oncology has lower revenue, but higher earnings than Zenas BioPharma. CG Oncology is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	220.11	-$377.74M	-$8.99	N/A
CG Oncology	$4.04M	1,732.21	-$160.99M	-$2.69	N/A

Zenas BioPharma has a beta of -1.03, indicating that its share price is 203% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

Zenas BioPharma currently has a consensus target price of $45.71, indicating a potential upside of 35.37%. CG Oncology has a consensus target price of $83.18, indicating a potential upside of 5.36%. Given Zenas BioPharma's higher possible upside, equities analysts clearly believe Zenas BioPharma is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Zenas BioPharma has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-122.45%	-58.04%
CG Oncology	-3,602.68%	-25.20%	-23.98%

In the previous week, CG Oncology had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for CG Oncology and 4 mentions for Zenas BioPharma. CG Oncology's average media sentiment score of 0.77 beat Zenas BioPharma's score of 0.14 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CG Oncology beats Zenas BioPharma on 11 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Zenas BioPharma (NASDAQ:ZBIO) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Cogent Biosciences presently has a consensus target price of $49.40, indicating a potential upside of 34.24%. Zenas BioPharma has a consensus target price of $45.71, indicating a potential upside of 35.37%. Given Zenas BioPharma's higher possible upside, analysts clearly believe Zenas BioPharma is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Cogent Biosciences has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.03, suggesting that its share price is 203% less volatile than the broader market.

Cogent Biosciences' return on equity of -84.47% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Zenas BioPharma	N/A	-122.45%	-58.04%

In the previous week, Cogent Biosciences had 15 more articles in the media than Zenas BioPharma. MarketBeat recorded 19 mentions for Cogent Biosciences and 4 mentions for Zenas BioPharma. Cogent Biosciences' average media sentiment score of 0.87 beat Zenas BioPharma's score of 0.14 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cogent Biosciences has higher earnings, but lower revenue than Zenas BioPharma. Cogent Biosciences is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Zenas BioPharma	$10M	220.11	-$377.74M	-$8.99	N/A

Summary

Cogent Biosciences beats Zenas BioPharma on 10 of the 13 factors compared between the two stocks.

How does Zenas BioPharma compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Zenas BioPharma (NASDAQ:ZBIO) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Mirum Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.03, suggesting that its share price is 203% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Zenas BioPharma. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 4 mentions for Zenas BioPharma. Mirum Pharmaceuticals' average media sentiment score of 1.29 beat Zenas BioPharma's score of 0.14 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zenas BioPharma has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Zenas BioPharma	N/A	-122.45%	-58.04%

Mirum Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.22	-$23.36M	-$14.55	N/A
Zenas BioPharma	$10M	220.11	-$377.74M	-$8.99	N/A

Mirum Pharmaceuticals presently has a consensus target price of $137.33, suggesting a potential upside of 40.02%. Zenas BioPharma has a consensus target price of $45.71, suggesting a potential upside of 35.37%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Mirum Pharmaceuticals beats Zenas BioPharma on 11 of the 15 factors compared between the two stocks.

Get Zenas BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBIO vs. The Competition

Export

Metric	Zenas BioPharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.06B	$4.00B	$7.34B	$12.72B
Dividend Yield	N/A	3.63%	2.53%	11.02%
P/E Ratio	-3.76	6.85	210.65	20.75
Price / Sales	220.11	1,381.21	634.79	96.73
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	8.91	16.86	13.14	6.25
Net Income	-$377.74M	-$22.76M	$3.46B	$347.86M
7 Day Performance	5.83%	4.71%	3.23%	1.57%
1 Month Performance	11.12%	12.26%	8.82%	5.24%
1 Year Performance	103.93%	60.84%	27.70%	17.87%

Zenas BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBIO Zenas BioPharma	2.7273 of 5 stars	$33.77 +6.7%	$45.71 +35.4%	+85.1%	$2.06B	$10M	N/A	N/A
TGTX TG Therapeutics	3.4331 of 5 stars	$50.26 +2.0%	$63.00 +25.3%	+90.3%	$7.46B	$616.29M	18.34	290
ORKA Oruka Therapeutics	2.9644 of 5 stars	$113.08 +0.4%	$134.30 +18.8%	+563.3%	$7.35B	N/A	N/A	N/A	Positive News Gap Up
CGON CG Oncology	2.5687 of 5 stars	$76.29 -1.1%	$83.18 +9.0%	+190.6%	$6.65B	$4.04M	N/A	61
COGT Cogent Biosciences	2.9761 of 5 stars	$37.40 -1.2%	$49.40 +32.1%	+198.9%	$6.58B	N/A	N/A	80	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZBIO) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. TGTX, ORKA, CGON, COGT, and MIRM

How does Zenas BioPharma compare to TG Therapeutics?

Summary

How does Zenas BioPharma compare to Oruka Therapeutics?

Summary

How does Zenas BioPharma compare to CG Oncology?

Summary

How does Zenas BioPharma compare to Cogent Biosciences?

Summary

How does Zenas BioPharma compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. TGTX, ORKA, CGON, COGT, and MIRM

How does Zenas BioPharma compare to TG Therapeutics?

Do insiders and institutionals believe in TGTX or ZBIO?

Is TGTX or ZBIO more profitable?

Do analysts prefer TGTX or ZBIO?

Which has more volatility & risk, TGTX or ZBIO?

Which has stronger valuation and earnings, TGTX or ZBIO?

Does the media favor TGTX or ZBIO?

Summary

How does Zenas BioPharma compare to Oruka Therapeutics?

Is ZBIO or ORKA more profitable?

Does the media refer more to ZBIO or ORKA?

Which has higher earnings & valuation, ZBIO or ORKA?

Do analysts rate ZBIO or ORKA?

Do insiders and institutionals hold more shares of ZBIO or ORKA?

Which has more volatility & risk, ZBIO or ORKA?

Summary

How does Zenas BioPharma compare to CG Oncology?

Do insiders and institutionals have more ownership in ZBIO or CGON?

Which has better valuation & earnings, ZBIO or CGON?

Which has more risk & volatility, ZBIO or CGON?

Do analysts recommend ZBIO or CGON?

Is ZBIO or CGON more profitable?

Does the media prefer ZBIO or CGON?

Summary

How does Zenas BioPharma compare to Cogent Biosciences?

Do analysts prefer COGT or ZBIO?

Which has more volatility and risk, COGT or ZBIO?

Is COGT or ZBIO more profitable?

Does the media prefer COGT or ZBIO?

Which has stronger valuation & earnings, COGT or ZBIO?

Summary

How does Zenas BioPharma compare to Mirum Pharmaceuticals?

Which has more volatility & risk, MIRM or ZBIO?

Does the media refer more to MIRM or ZBIO?

Is MIRM or ZBIO more profitable?

Which has better valuation & earnings, MIRM or ZBIO?

Do analysts rate MIRM or ZBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools